CINC Corp. Logo

CINC Corp.

Offers AI marketing analytics and SEO tools leveraging a vast Japanese keyword dataset.

4378 | T

Overview

Corporate Details

ISIN(s):
JP3372170005
LEI:
Country:
Japan
Address:
港区虎ノ門一丁目21−19
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

CINC Corp. is a data solutions company that utilizes big data, machine learning, and artificial intelligence to provide marketing analytics. Founded in 2014, the company develops and offers research and analysis tools designed to optimize digital marketing operations. Its core product, Keywordmap, leverages a proprietary and extensive Japanese keyword dataset to support clients with SEO strategy, competitor analysis, and market research. CINC aims to transform complex data into actionable insights, enabling businesses to enhance their online presence and strategic decision-making.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-13 09:01
Interim Report
確認書
Japanese 8.7 KB
2025-06-13 09:00
Interim Report
半期報告書-第12期(2024/11/01-2025/10/31)
Japanese 192.0 KB
2025-04-02 02:31
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.5 KB
2025-03-19 08:00
Major Shareholding Notification
臨時報告書
Japanese 20.7 KB
2025-01-30 04:18
Post-Annual General Meeting Information
臨時報告書
Japanese 24.3 KB
2025-01-29 08:01
Registration Form
確認書
Japanese 8.8 KB
2025-01-29 08:01
Governance Information
内部統制報告書-第11期(2023/11/01-2024/10/31)
Japanese 23.8 KB
2025-01-29 08:00
Registration Form
有価証券報告書-第11期(2023/11/01-2024/10/31)
Japanese 1020.3 KB
2024-09-04 08:12
Post-Annual General Meeting Information
訂正臨時報告書
Japanese 30.9 KB
2024-07-29 02:31
Post-Annual General Meeting Information
臨時報告書
Japanese 22.0 KB
2024-06-14 09:00
Report Publication Announcement
確認書
Japanese 8.8 KB
2024-06-14 09:00
Quarterly Report
四半期報告書-第11期第2四半期(2024/02/01-2024/04/30)
Japanese 207.4 KB
2024-03-14 08:01
Report Publication Announcement
確認書
Japanese 8.8 KB
2024-03-14 08:00
Quarterly Report
四半期報告書-第11期第1四半期(2023/11/01-2024/01/31)
Japanese 159.0 KB
2024-01-29 08:01
Post-Annual General Meeting Information
臨時報告書
Japanese 23.7 KB

Automate Your Workflow. Get a real-time feed of all CINC Corp. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CINC Corp.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CINC Corp. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Noile-Immune Biotech Inc. Logo
Developing PRIME technology-enhanced CAR-T cell immunotherapies for treating solid tumors.
Japan
4893
NRGene Technologies Ltd. Logo
AI-powered genomic analysis software to accelerate and optimize plant and animal breeding.
Israel
NRGN
Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150

Talk to a Data Expert

Have a question? We'll get back to you promptly.